Comparison of media for agar dilution susceptibility testing ofBordetella pertussis andBordetella parapertussis

Hoppe, J. E.; Tschirner, Thomas

doi:10.1007/bf01690992

Cited by 13 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The test procedure was similar to that in our previous studies (5,6). Test substances of all antimicrobial agents were supplied by Hoechst Marion Roussel (Romainville, France) and were dissolved and diluted according to the manufacturer's instructions.…”

mentioning

confidence: 99%

In Vitro Susceptibilities of Bordetella pertussis and Bordetella parapertussis to Two Ketolides (HMR 3004 and HMR 3647), Four Macrolides (Azithromycin, Clarithromycin, Erythromycin A, and Roxithromycin), and Two Ansamycins (Rifampin and Rifapentine)

Hoppe

Bryskier²

1998

Antimicrob Agents Chemother

View full text Add to dashboard Cite

When tested by agar dilution on Mueller-Hinton agar supplemented with 5% horse blood, the ketolides HMR 3004 and HMR 3647 were slightly more active (MIC at which 90% of the isolates were inhibited [MIC90], 0.03 μg/ml) against Bordetella pertussis than azithromycin, clarithromycin, erythromycin A, and roxithromycin. Azithromycin (MIC90, 0.06 μg/ml) was the most active compound against B. parapertussis. Rifampin and rifapentine were considerably less active.

show abstract

mentioning

confidence: 99%

In Vitro Susceptibilities of Bordetella pertussis and Bordetella parapertussis to Two Ketolides (HMR 3004 and HMR 3647), Four Macrolides (Azithromycin, Clarithromycin, Erythromycin A, and Roxithromycin), and Two Ansamycins (Rifampin and Rifapentine)

Hoppe

Bryskier²

1998

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…pertussis was subcultured onto Mueller-Hinton agar (MHA) supplemented with 5% sheep blood for 48 h at 36°C in ambient air supplemented with 5% CO 2 . The MICs of solithromycin and comparator drugs were determined by agar dilution methodology as described by CLSI document M7-A9 (13) and in Mueller-Hinton agar supplemented with 5% horse blood as recommended by Hoppe and Tschirner (14). Organism suspensions harvested from 48-h cultures were adjusted to yield a final test inoculum of 10 4 CFU/spot.…”

Section: Methodsmentioning

confidence: 99%

In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen

Hardy

Vicino

Fernandes

2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

There has been an increase in the number of pertussis cases reported since the introduction of the acellular pertussis vaccine. While children that present with pertussis have a characteristic whooping cough, adults can simply have a persistent, nonspecific cough and remain undiagnosed. Macrolide antibiotics, such as azithromycin, are the currently recommended treatment for pertussis. Solithromycin is a new macrolide and the first fluoroketolide with broad activity against a wide spectrum of bacterial pathogens and has completed clinical development for community-acquired bacterial pneumonia. This study reports the potent in vitro activity of solithromycin against a collection of recent isolates of Bordetella pertussis.

show abstract

“…Because data on the clinical effectiveness of antibiotic treatment against B. parapertussis are limited, treatment decisions should be based on clinical judgment [58].…”

Section: Treatmentmentioning

confidence: 99%

Update on Epidemiology, Diagnosis, and Treatment of Pertussis

Hozbor¹

2018

Pertussis - Disease, Control and Challenges

View full text Add to dashboard Cite

Pertussis, commonly known as whooping cough, is one of the most common vaccinepreventable infections. In adolescents and adults, infection may result in a protracted cough and is occasionally associated with substantial morbidity. In children and particularly infants, morbidity is more often substantial and the disease may be fatal. Two types of vaccines against pertussis exist: whole-cell vaccines (wP), developed in the 1940s, containing the entire inactivated Bordetella pertussis organism, and acellular vaccines (aP) constituting of 1-5 purified bacterial proteins. The aPs were developed in the 1970s in order to diminish the adverse effects that could occur in the wP vaccinations. In many industrialized countries, aP replaced the wP formulations; however, wPs are still used for primary vaccination doses in developing countries. The massive use of both types of vaccines significantly reduced the morbidity and mortality associated with the disease; nevertheless, pertussis is still an important public health problem. In fact, pertussis incidence has increased in many countries, with large sustained epidemics occurring most notably in developed countries that only use acellular vaccine for all the doses included in the calendar. This chapter focuses on some recent developments in the areas of epidemiology, diagnosis, and treatment of pertussis.

show abstract

Comparison of media for agar dilution susceptibility testing ofBordetella pertussis andBordetella parapertussis

Cited by 13 publications

References 21 publications

In Vitro Susceptibilities of Bordetella pertussis and Bordetella parapertussis to Two Ketolides (HMR 3004 and HMR 3647), Four Macrolides (Azithromycin, Clarithromycin, Erythromycin A, and Roxithromycin), and Two Ansamycins (Rifampin and Rifapentine)

In Vitro Susceptibilities of Bordetella pertussis and Bordetella parapertussis to Two Ketolides (HMR 3004 and HMR 3647), Four Macrolides (Azithromycin, Clarithromycin, Erythromycin A, and Roxithromycin), and Two Ansamycins (Rifampin and Rifapentine)

In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen

Update on Epidemiology, Diagnosis, and Treatment of Pertussis

Contact Info

Product

Resources

About